CA2865282A1 - Elevated psma identifies lethal prostate cancers - Google Patents

Elevated psma identifies lethal prostate cancers Download PDF

Info

Publication number
CA2865282A1
CA2865282A1 CA2865282A CA2865282A CA2865282A1 CA 2865282 A1 CA2865282 A1 CA 2865282A1 CA 2865282 A CA2865282 A CA 2865282A CA 2865282 A CA2865282 A CA 2865282A CA 2865282 A1 CA2865282 A1 CA 2865282A1
Authority
CA
Canada
Prior art keywords
psma
imaging
expression
agent
prostate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2865282A
Other languages
English (en)
French (fr)
Inventor
Neil H. Bander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell University
Original Assignee
Cornell University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell University filed Critical Cornell University
Publication of CA2865282A1 publication Critical patent/CA2865282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Reproductive Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
CA2865282A 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers Abandoned CA2865282A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602900P 2012-02-24 2012-02-24
US61/602,900 2012-02-24
PCT/US2013/000045 WO2013126147A2 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Publications (1)

Publication Number Publication Date
CA2865282A1 true CA2865282A1 (en) 2013-08-29

Family

ID=49003541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2865282A Abandoned CA2865282A1 (en) 2012-02-24 2013-02-22 Elevated psma identifies lethal prostate cancers

Country Status (6)

Country Link
US (2) US20130225541A1 (enExample)
EP (2) EP3064945A1 (enExample)
JP (2) JP6501524B2 (enExample)
CA (1) CA2865282A1 (enExample)
HK (1) HK1205788A1 (enExample)
WO (1) WO2013126147A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1202256A1 (en) * 2012-02-28 2015-09-25 Cornell University Psma as a biomarker for androgen activity in prostate cancer
US10340046B2 (en) 2016-10-27 2019-07-02 Progenics Pharmaceuticals, Inc. Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications
CA3050085A1 (en) 2017-01-20 2018-07-26 Juno Therapeutics Gmbh Cell surface conjugates and related cell compositions and methods
CA3056261A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
US12602772B2 (en) 2018-01-08 2026-04-14 Progenics Pharmaceuticals, Inc. Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
CN113272859B (zh) 2019-01-07 2025-04-04 西尼诊断公司 用于平台中立性全身图像分段的系统及方法
TWI872062B (zh) 2019-04-24 2025-02-11 美商普吉尼製藥公司 用於偵測轉移之骨掃描影像之自動及互動式分析系統、裝置及方法
US12417533B2 (en) 2019-09-27 2025-09-16 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
US11900597B2 (en) 2019-09-27 2024-02-13 Progenics Pharmaceuticals, Inc. Systems and methods for artificial intelligence-based image analysis for cancer assessment
IL320607A (en) 2020-03-26 2025-07-01 Ramirez Fort Marigdalia Kaleth Ultraviolet radiation treatments
US11721428B2 (en) 2020-07-06 2023-08-08 Exini Diagnostics Ab Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions
AU2022361659A1 (en) 2021-10-08 2024-03-21 Exini Diagnostics Ab Systems and methods for automated identification and classification of lesions in local lymph and distant metastases
CN119791845B (zh) * 2025-01-03 2026-05-08 北京大学第一医院(北京大学第一临床医学院) 一种降低前列腺根治性切除术后切缘阳性的治疗设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098885A1 (en) * 2001-02-07 2002-12-12 Beth Israel Deaconess Medical Center Modified psma ligands and uses related thereto
JP4619651B2 (ja) * 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
ATE408712T1 (de) * 2003-01-10 2008-10-15 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
WO2005021709A2 (en) * 2003-05-29 2005-03-10 Diadexus, Inc. Cln101 antibodies
RU2450832C2 (ru) * 2006-10-25 2012-05-20 Конинклейке Филипс Электроникс Н.В. Контрастные вещества для детекции рака предстательной железы
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
EP2281004A4 (en) * 2008-04-14 2012-02-15 Proscan Rx Pharma Inc PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
WO2010065940A1 (en) * 2008-12-04 2010-06-10 The Regents Of The University Of California Materials and methods for determining diagnosis and prognosis of prostate cancer
EP3495000A1 (en) * 2009-02-17 2019-06-12 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US8772226B2 (en) * 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer

Also Published As

Publication number Publication date
JP2015513083A (ja) 2015-04-30
EP3064945A1 (en) 2016-09-07
EP2817629A2 (en) 2014-12-31
WO2013126147A3 (en) 2014-12-24
JP6501524B2 (ja) 2019-04-17
US20130225541A1 (en) 2013-08-29
WO2013126147A2 (en) 2013-08-29
HK1205788A1 (en) 2015-12-24
JP2019144254A (ja) 2019-08-29
US20180088120A1 (en) 2018-03-29
EP2817629A4 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
US20180088120A1 (en) Elevated PSMA Identifies Lethal Prostate Cancers
Donato et al. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions “invisible” on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology
Sadeghi-Naini et al. Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture
De Bree et al. Advances in diagnostic modalities to detect occult lymph node metastases in head and neck squamous cell carcinoma
Créhange et al. Management of prostate cancer patients with lymph node involvement: a rapidly evolving paradigm
Song et al. Polyamine-targeting gefitinib prodrug and its near-infrared fluorescent theranostic derivative for monitoring drug delivery and lung cancer therapy
Kinoshita et al. Prognostic significance of hypoxic PET using 18F-FAZA and 62Cu-ATSM in non-small-cell lung cancer
HK1223847A1 (zh) 使用spect/ct分析进行癌症分期的方法
Khandani et al. Positron emission tomography in renal cell carcinoma: an imaging biomarker in development
Liu et al. PET/CT using 68Ga‐PSMA‐617 versus 18F‐fluorodeoxyglucose to differentiate low‐and high‐grade gliomas
Zhou et al. Nucleophosmin 1 overexpression correlates with 18F-FDG PET/CT metabolic parameters and improves diagnostic accuracy in patients with lung adenocarcinoma
Wang et al. Application of near-infrared fluorescence imaging in the accurate assessment of surgical margins during breast-conserving surgery
Dong et al. 18F-PSMA-1007 PET/CT-derived semi-quantitative parameters for risk stratification of newly diagnosed prostate cancer
Brassell et al. Update on magnetic resonance imaging, ProstaScint, and novel imaging in prostate cancer
Sarkaria et al. Intraoperative molecular imaging with pafolacianine: histologic characteristics of identified nodules
Houvast et al. Prediction of biomarker expression on primary pancreatic ductal adenocarcinoma tissues using Fine-Needle biopsies: paving the way for a Patient-Tailored molecular imaging approach
Mishra et al. Advanced and futuristic approaches for breast cancer diagnosis
Zhou et al. Value of 11C-Choline PET/CT-based multi-metabolic parameter combination in distinguishing early-stage prostate cancer from benign prostate diseases
Patel et al. The challenges of integrating molecular imaging into the optimization of cancer therapy
Jiang et al. Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2
Kang et al. Sodium/iodide symporter expression in primary lung cancer and comparison with glucose transporter 1 expression
Greco et al. Impact of the diagnostic methods on the therapeutic strategies
Nakamura et al. Diagnostic significance of FDG-PET and argyrophilic nucleolar organizer regions (AgNORs) in oral squamous cell carcinoma
Tao et al. Noninvasive Evaluation of HER2 Expression and Heterogeneity in Urothelial Carcinoma on 68Ga-HER2-affibody PET/CT
Hafez et al. Dynamin-2 and Angiopoietin-like protein 2 as novel prognostic markers in papillary thyroid carcinoma

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180222

FZDE Discontinued

Effective date: 20201008